CTNM
NASDAQContineum Therapeutics Inc.
$12.41+0.01 (+0.08%)
News25/Ratings5
Price$12.41+0.10 (+0.81%)
01:30 PM07:45 PM
News · 26 weeks48-78%
2025-10-262026-04-19
Mix3090d
- Insider14(47%)
- Other9(30%)
- SEC Filings6(20%)
- Offering1(3%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Contineum Therapeutics Inc.SCHEDULE 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)
- INSIDERSEC Form 4 filed by Lorrain Daniel S.4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- PRContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on March 12, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common stock to one new non-executive employee under the Company's 2026 Employment Inducement Equity Incentive Plan. The award was granted as an inducement material to the new employee's employment with the Company in accordance with Nasdaq L
- SECSEC Form S-8 filed by Contineum Therapeutics Inc.S-8 - Contineum Therapeutics, Inc. (0001855175) (Filer)
- SECSEC Form 424B5 filed by Contineum Therapeutics Inc.424B5 - Contineum Therapeutics, Inc. (0001855175) (Filer)
- SECSEC Form 10-K filed by Contineum Therapeutics Inc.10-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
- SECContineum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
- PRContineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones- Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) - Topline data from the exploratory PIPE-791 Phase 1b trial in patients with chronic pain is expected in the second quarter of 2026 Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2025 financial results and affirmed its key clinical development milestones. "We're off to a strong start in 2026, having recently dosed t
- PRContineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare ConferenceContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies
- INSIDERChief Scientific Officer Lorrain Daniel S. sold $62,585 worth of shares (4,170 units at $15.01), decreasing direct ownership by 3% to 151,882 units (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERCMO & Head of Development Watkins Tim exercised 3,611 shares at a strike of $4.50 and sold $54,220 worth of shares (3,611 units at $15.02) (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERCEO and President Stengone Carmine N. exercised 7,100 shares at a strike of $1.26 and sold $113,728 worth of shares (7,100 units at $16.02) (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERChief Scientific Officer Lorrain Daniel S. exercised 8,124 shares at a strike of $1.01 and sold $130,164 worth of shares (8,124 units at $16.02) (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERChief Scientific Officer Lorrain Daniel S. exercised 100 shares at a strike of $1.01 and sold $1,600 worth of shares (100 units at $16.00) (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- PRContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on February 17, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common stock to one new non-executive employee under the Company's 2026 Employment Inducement Equity Incentive Plan. The award was granted as an inducement material to the new employee's employment with the Company in accordance with Nasda
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)
- SECSEC Form SCHEDULE 13G filed by Contineum Therapeutics Inc.SCHEDULE 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)
- SECSEC Form SCHEDULE 13G filed by Contineum Therapeutics Inc.SCHEDULE 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)
- INSIDERCEO and President Stengone Carmine N. sold $6,400 worth of shares (400 units at $16.00) and exercised 400 shares at a strike of $1.26 (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERChief Scientific Officer Lorrain Daniel S. exercised 400 shares at a strike of $1.01 and sold $6,400 worth of shares (400 units at $16.00) (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERChief Scientific Officer Lorrain Daniel S. sold $62,305 worth of shares (4,170 units at $14.94), decreasing direct ownership by 3% to 156,052 units (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- SECSEC Form 144 filed by Contineum Therapeutics Inc.144 - Contineum Therapeutics, Inc. (0001855175) (Subject)
- INSIDERSEC Form 4 filed by General Counsel and Corp Sec Healy John Stephen4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Slover Peter T4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by CEO and President Stengone Carmine N.4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)